Cargando…

Efficacy of Bravecto(®) Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) for the prevention of aelurostrongylosis in experimentally infected cats

BACKGROUND: The feline lungworm Aelurostrongylus abstrusus affects the lower respiratory tract in cats worldwide. As infections may lead to chronic respiratory changes or even death, preventive treatment in cats with outdoor access is warranted. METHODS: The preventive efficacy of a spot-on solution...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raue, Katharina, Rohdich, Nadja, Hauck, Daniela, Zschiesche, Eva, Morelli, Simone, Traversa, Donato, Di Cesare, Angela, Roepke, Rainer K. A., Strube, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885211/ https://www.ncbi.nlm.nih.gov/pubmed/33593394 http://dx.doi.org/10.1186/s13071-021-04610-y

Ejemplares similares

Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats
por: Rohdich, Nadja, et al.
Publicado: (2018)

A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto® Plus)
por: Rohdich, Nadja, et al.
Publicado: (2018)

Efficacy of fluralaner plus moxidectin (Bravecto® Plus spot-on solution for cats) against Otodectes cynotis infestations in cats
por: Taenzler, Janina, et al.
Publicado: (2018)

A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto™ (fluralaner) against Frontline™ (fipronil) in flea- and tick-infested dogs
por: Rohdich, Nadja, et al.
Publicado: (2014)

Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats
por: Walther, Feli M., et al.
Publicado: (2018)

Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs
por: Taenzler, Janina, et al.
Publicado: (2014)

The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs
por: Wengenmayer, Christina, et al.
Publicado: (2014)

A Comparison of Copromicroscopic and Molecular Methods for the Diagnosis of Cat Aelurostrongylosis
por: Morelli, Simone, et al.
Publicado: (2022)

Investigation of the efficacy of fluralaner spot-on (Bravecto®) against infestations of Ixodes holocyclus on cats
por: Fisara, Petr, et al.
Publicado: (2018)

Efficacy of a spot-on combination of fluralaner plus moxidectin (Bravecto(®) Plus) in cats following repeated experimental challenge with a field isolate of Ctenocephalides felis
por: Fisara, Petr, et al.
Publicado: (2019)

Efficacy of two topical fluralaner formulations (Bravecto®; Bravecto® Plus) against Asian longhorned tick (Haemaphysalis longicornis) infestations of cats
por: Petersen, Melissa, et al.
Publicado: (2023)

Efficacy of imidacloprid 10%/moxidectin 1% spot-on formulation (Advocate®) in the prevention and treatment of feline aelurostrongylosis
por: Heuer, Lea, et al.
Publicado: (2020)

Efficacy of orally and topically administered fluralaner (Bravecto(®)) for treatment of client-owned dogs with sarcoptic mange under field conditions
por: Chiummo, Rafael, et al.
Publicado: (2020)

A European field assessment of the efficacy of fluralaner (Bravecto(®)) chewable and spot-on formulations for treatment of dogs with generalized demodicosis
por: Petersen, Ivo, et al.
Publicado: (2020)

Fluralaner 5.46% (w/w) flavored chewable tablet (Bravecto(®) 1-Month) is effective for treatment of canine generalized demodicosis
por: Rohdich, Nadja, et al.
Publicado: (2022)

Flea and tick treatment satisfaction, preference, and adherence of US cat owners prescribed topical fluralaner (Bravecto(®) Topical Solution for Cats)
por: Lavan, Robert, et al.
Publicado: (2021)

Correction to: Fluralaner 5.46% (w/w) favored chewable tablet (Bravecto® 1-Month) is effective for treatment of canine generalized demodicosis
por: Rohdich, Nadja, et al.
Publicado: (2022)

Publisher Correction: Efficacy of two topical fluralaner formulations (Bravecto®; Bravecto® Plus) against Asian longhorned tick (Haemaphysalis longicornis) infestations of cats
por: Petersen, Melissa, et al.
Publicado: (2023)

A quantitative evaluation of the extent of fluralaner uptake by ticks (Ixodes ricinus, Ixodes scapularis) in fluralaner (Bravecto(TM)) treated vs. untreated dogs using the parameters tick weight and coxal index
por: Williams, Heike, et al.
Publicado: (2015)

Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel
por: Walther, Feli M, et al.
Publicado: (2014)

Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin)
por: Walther, Feli M, et al.
Publicado: (2014)

Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs
por: Walther, Feli M., et al.
Publicado: (2015)

Efficacy of orally administered fluralaner (Bravecto(TM)) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs
por: Fourie, Josephus J, et al.
Publicado: (2015)

Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto(®) Chew (25 mg/kg fluralaner) or Simparica TRIO(®) (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
por: Reif, Kathryn E., et al.
Publicado: (2023)

Safety of concurrent treatment of cats with fluralaner and emodepsid–praziquantel
por: Walther, Feli M., et al.
Publicado: (2016)

First Case of Clinical Cat Aelurostrongylosis in the Brazilian Amazon: Clinical and Molecular Insights
por: da Silva Lima, Wilison, et al.
Publicado: (2021)

Do All Roads Lead to Rome? The Potential of Different Approaches to Diagnose Aelurostrongylus abstrusus Infection in Cats
por: Raue, Katharina, et al.
Publicado: (2021)

Efficacy of fluralaner (Bravecto™ chewable tablets) for the treatment of naturally acquired Linognathus setosus infestations on dogs
por: Kohler-Aanesen, Heike, et al.
Publicado: (2017)

Controlled field study evaluating the clinical efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural cat aelurostrongylosis
por: Crisi, Paolo Emidio, et al.
Publicado: (2020)

Erratum to: Safety of concurrent treatment of cats with fluralaner and emodepsid-praziquantel
por: Walther, Feli M., et al.
Publicado: (2016)

Efficacy of fluralaner flavored chews (Bravecto®) administered to dogs against the adult cat flea, Ctenocephalides felis felis and egg production
por: Dryden, Michael W, et al.
Publicado: (2015)

Efficacy of fluralaner against Otodectes cynotis infestations in dogs and cats
por: Taenzler, Janina, et al.
Publicado: (2017)

Efficacy of a spot-on combination containing 10% w/v imidacloprid and 1% w/v moxidectin for the treatment of troglostrongylosis in experimentally infected cats
por: Traversa, Donato, et al.
Publicado: (2022)

Erratum to: Efficacy of fluralaner flavored chews (Bravecto®) administered to dogs against the adult cat flea, Ctenocephalides felis felis and egg production
por: Dryden, Michael W., et al.
Publicado: (2015)

Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs treated orally with fluralaner chewable tablets (Bravecto™)
por: Taenzler, Janina, et al.
Publicado: (2015)

Comparative pharmacokinetics of fluralaner in dogs and cats following single topical or intravenous administration
por: Kilp, Susanne, et al.
Publicado: (2016)

Treatment of dogs with Bravecto(®) (fluralaner) reduces mosquito survival and fecundity
por: Evans, Christopher Charles, et al.
Publicado: (2023)

Field efficacy of fluralaner (Bravecto(®) chewable tablets) for preventing Babesia canis infection transmitted by Dermacentor reticulatus ticks to dogs
por: Chiummo, Rafael, et al.
Publicado: (2023)

Nicotine delivery and user reactions to Juul EU (20 mg/ml) compared with Juul US (59 mg/ml), cigarettes and other e-cigarette products
por: Phillips-Waller, Anna, et al.
Publicado: (2020)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1l719ggtbd19g57crmbmsrt7dd